Ahn, D.H.; Bekaii-Saab, T.S.; Yuan, C.; Kurtinecz, M.; Pan, X.; Vassilev, Z.; Pisa, F.; Ostojic, H.
Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA. Cancers 2025, 17, 969.
https://doi.org/10.3390/cancers17060969
AMA Style
Ahn DH, Bekaii-Saab TS, Yuan C, Kurtinecz M, Pan X, Vassilev Z, Pisa F, Ostojic H.
Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA. Cancers. 2025; 17(6):969.
https://doi.org/10.3390/cancers17060969
Chicago/Turabian Style
Ahn, Daniel H., Tanios S. Bekaii-Saab, Chengbo Yuan, Milena Kurtinecz, Xiaoyun Pan, Zdravko Vassilev, Federica Pisa, and Helene Ostojic.
2025. "Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA" Cancers 17, no. 6: 969.
https://doi.org/10.3390/cancers17060969
APA Style
Ahn, D. H., Bekaii-Saab, T. S., Yuan, C., Kurtinecz, M., Pan, X., Vassilev, Z., Pisa, F., & Ostojic, H.
(2025). Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA. Cancers, 17(6), 969.
https://doi.org/10.3390/cancers17060969
